The Development of Microfluidic Chip for the Capture of Breast Cancer Cells and Its Effect on Captured Cells

doi:10.13523/j.cb.20150608

China Biotechnology

2015, Vol. 35

Issue (6): 46-53 DOI: 10.13523/j.cb.20150608

The Development of Microfluidic Chip for the Capture of Breast Cancer Cells and Its Effect on Captured Cells

SANG Wei-wei^1,2, CHANG Ya-nan¹, LI Juan¹

1. Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China;
2. School of Life Sciences, Anhui University, Hefei 230601, China

Download:

HTML

PDF(1540KB) HTML
Export: BibTeX | EndNote (RIS)

Abstract

Objective: To achieve an effective capture efficiency of breast cancer cell (MDA - MB-231) by the microfluidic chip, and then analyse the changes of the target genes FN1, ITGA6 and LAMB3 expressing level in the tumor cells. Methods: The substrate of microfluidic chip was coupled with MUC1 antibodies, which could capture the tumor cells by the antigen on the cell surface. The conditions of cell capture were optimized to gain high cell capture efficiency. The captured cells were released by trypsin digestion and then the released cells were collected and re-cultured. The normal and re-cultivated cells were incubated with 1μmol/L doxorubicin for 24h respectively. Then the RNA in the cells was extracted and reversed to synthesize DNA and the target genes FN1, ITGA6 and LAMB3 were amplified by reverse transcriptase polymerase chain reaction (RT-PCR). Results: The tumor cells can be effectively captured by the microfluidic bio-chip after MUC1 antibodies were modified on the surface of chip and the capture rate can reach 80%. The cells release efficiency was as high as 98% and the released cells still had high viability which could be re-cultured. Doxorubicin could inhibit the expression quantity of FN1, ITGA6 and LAMB3 in normal and re-cultivated MDA-MB-231 cells. Conclusion: The tumor cells can be captured effectively by the microfluidic chip and re-cultured. The expressions of genes of the cells were not interfered remarkably for pre or post-captured. All of these would lay the foundation for the following related research such as biochemistry and molecular biology research, the efficacy evaluation analysis of antitumor drugs and so on.

Key words： Microfluidic device Capture and re-culture Doxorubicin MDA-MB-231

Received: 17 March 2015 Published: 25 June 2015

ZTFLH:

Q819

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

SANG Wei-wei, CHANG Ya-nan, LI Juan. The Development of Microfluidic Chip for the Capture of Breast Cancer Cells and Its Effect on Captured Cells. China Biotechnology, 2015, 35(6): 46-53.

URL:

https://manu60.magtech.com.cn/biotech/10.13523/j.cb.20150608 OR https://manu60.magtech.com.cn/biotech/Y2015/V35/I6/46

[1] Asworth T R. A case of cancer in which cells similar to those in tumors were seen in the blood after death. Aust Med J,1869,14:146-149.

[2] Paterlini-Brechot P, Benali N L.Circulating tumor cells(CTC) detection:clinical impact and future directions. Cancer Lett,2007,253(2):180-204.

[3] Krebs M G, Metcalf R L, Carter L, et al. Molecular analysis of circulating tumor cells-biology and biomarkers. Nat RevClin Oncol, 2014,11(3):129-144.

[4] Bhagat A A S, Bow H, Hou H W, et al. Microfluidics for cell seperation. Med Bio Eng Comput,2010,48(10):999-1014.

[5] Feng X J, Du W, Luo Q M, et al. Microfluidic chip: next-generation platform for systems biology. Anal Chim Acta,2009,650(1):83-97.

[6] Alix-Panabieres C, Vendrell J P, Pelle O, et al. Detection and characterization of putative metastatic precursor cells in cancer patients. Clin Chem,2007,53(3):537-539.

[7] 鲁藜,邓华瑜,范维珂. MUC1的表达与乳腺癌细胞粘附的关系.癌症,2004,23(11):1294-1296. Lu L, Deng Y H, Fan W K. Correlation of MUC1 expression to adhesion of breast cancer cell line MDA-MB-231. Chinese Journal of Cancer,2004,23(11):1294-1296.

[8] Kang Y B, Massague J. Epithelial-mesenchymal transitions:Twist in development and metastasis. Cell,2004,118(3):277-279.

[9] Friedl P, Wolf K. Tumour-cell invasion and migration: Diversity and escape mechanisms. Nat Rev Cancer,2003,3(5):362-374.

[10] Sheng W, Ogunwobi O O, Chen T, et al. Capture, release and culture of circulating tumor cells from pancreatic cancer patients using an enhanced mixing chip. Lab Chip,2014,14(1):89-98.

[11] Ghossein R A, Carusone L, Bhattacharya S. Polymerase chain reaction detection of micrometastases and circulating tumor cells:application to melanoma,prostate and thyroid carcinomas. Diagn Mol Pathol,1999,8(4):165-175.

[12] Mallory J C, Crudden G, Oliva A, et al. A novel group of genes regulates susceptibility to antineoplastic drugs in highly tumorigenic breast cancer cells. Mol Pharmacol, 2005,68(6):1747-1756.

[13] Zhang X L, Jonse P, Haswell S J. Attachment and detachment of living cells on modified microchannel surfaces in a microfiuidic-based lab-on-a-chip system. Chemical Engineering Journal,2008,135:82-88.

[14] 宋云飞,张健,张连伟. 循环肿瘤细胞的检测对乳腺癌诊治意义的研究现状.临床与病理杂志,2014,34(5):585-595. Song Y F, Zhang J, Zhang L W. The status quo of the detection of circulating tumor cells in breast cancer diagnosis and its significance. Journal of Clinical and Pathological Research,2014,34(5):585-595.

[15] 杜珍武,王茜,张玉成,等. 应用凝胶成像分析系统定量测定 DNA含量的检测范围.中国体视学与图像分析,2008,13(4):264-267. Du Z W, Wang Q, Zhang Y C, et al. Applicable range of quantitative detection of DNA content by gel imaging analysis system. Chinese Journal Stereology and Image Anlysis,2008,13(4):264-267.

[16] Riethdorf S, Fritsche H, Muller V, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer:A validation study of the CellSearch system. Clin Cancer Res,2007,13(3):920-928.

[1]	QIN Yao, ZHAO Hong-yan, ZHANG Wen-hang, WANG Dong-mei. miR146a Participates in Doxorubicin Cardiotoxicity Through Smad4[J]. China Biotechnology, 2017, 37(6): 31-36.

[2]	LIU Li-ping, ZHANG Chun, YIN Shuang, WANG Qi, ZHANG Yao, YU Rong, LIU Yong-dong, SU Zhi-guo. Design, Preparation, Characterization and Preliminary Evaluation of an Albumin Binding Peptide-Doxorubicin Conjugate[J]. China Biotechnology, 2017, 37(4): 68-75.

[3]	WU Jun, YAN Xin, SHAO Rong, DUAN Jing-hua. Study of Co-encapsulated Doxorubicin and Curcumin Poly(butyl cyanoacrylate) Nanoparticles and Reversion of Multidrug Resistance in MCF/ADR Cell Line[J]. China Biotechnology, 2013, 33(5): 35-43.

[4]	GUO Chun-fang, ZHANG Yang-de, WANG Ji-wei, PAN Yi-feng, LIAO Ming-mei, WANG Ning. Characterization and the Anti-tumor Effect of Doxorubicin Flexible Liposome in vitro[J]. China Biotechnology, 2013, 33(3): 9-14.

[5]	MA Wei-feng, YANG Fei-hua, ZHAO Hai-shan, DU Jun, CAI Shao-hui. Toxicity Evaluation of a FAPα-activated Targeting Anticancer Prodrug Z-GP-Dox in Zebrafish[J]. China Biotechnology, 2012, 32(07): 37-42.

[6]	XIE Qiu-ling, LU Jia, LIU Lan, ZHANG Chuan-yu, GUO Xin-yong, PENG Wen-dan, CHEN Xiao-jia. Study of Human PDGFR β Promoter in Different Human Breast Cancer Cells[J]. China Biotechnology, 2011, 31(04): 18-24.

Viewed

Full text

Abstract

Cited

Shared

Discussed